What to Do When a Claimant Is Prescribed Medicinal Cannabis

Navigate regulatory, clinical, and coverage considerations in claims management

Published: 3 April 2026 | Updated: 3 April 2026

Medicinal Cannabis in Claims: Emerging but Complex

Medicinal cannabis is increasingly prescribed in Australia and New Zealand for chronic pain, nausea, spasticity, and other conditions. As an insurer, you'll encounter claimants on cannabis products, and you need clarity on evidence, regulatory status, and your coverage obligations. The challenge is that medicinal cannabis is still evolving; evidence is emerging, regulatory frameworks differ between jurisdictions, and many claimants conflate medicinal use with recreational use. This article provides practical guidance to evaluate medicinal cannabis requests fairly, understand the regulatory landscape, and make informed coverage decisions that balance claimant access with evidence-based practice.

Regulatory Status and Legal Framework

Australia

In Australia, medicinal cannabis products are regulated as pharmaceutical products by the TGA (Therapeutic Goods Administration). Access occurs through the Special Access Scheme (SAS) or Authorised Prescriber schemes. Products include standardised cannabis oils, dried flower, and other formulations. Not all cannabis products are TGA-approved; many are accessed under SAS, which means they're prescribed off-label based on clinical judgment rather than formal approval.

New Zealand

In New Zealand, medicinal cannabis became legal in 2018 via the Medicinal Cannabis Scheme. Licensed producers supply products. Prescribers can recommend cannabis under specific conditions; the product and recommendation go through a licensing approval process. Access is more restricted than Australia's SAS scheme.

Evidence Base for Medicinal Cannabis

Evidence for medicinal cannabis is emerging but inconsistent. Strong evidence exists for:

• Chemotherapy-induced nausea and vomiting: Moderate evidence supporting efficacy
• Multiple sclerosis-related spasticity: Moderate evidence for symptom improvement
• Chronic pain (various types): Weak to moderate evidence; cannabis-derived compounds show benefit in some studies but heterogeneous results

Weaker or absent evidence for:

• Sleep disturbance alone
• Anxiety without specific diagnosis
• General "pain management" without specific indication
• Cognitive or mood symptoms as primary indication

This evidence landscape matters for your coverage decisions. Prescribing medicinal cannabis for indications with weak evidence (e.g., anxiety alone, insomnia) is not inappropriate but should trigger closer review and shorter trial periods before assessment.

Clinical Considerations in Claims

Cannabis and Cognitive Function

Cannabinoids, particularly THC (tetrahydrocannabinol), have dose-dependent cognitive effects including impaired attention, memory, and reaction time. In the injury recovery context, cognitive impairment is particularly problematic. A claimant working toward return-to-work while on cannabis products may face functional impairment not reflected in their subjective symptom report. This requires explicit assessment.

Cannabis and Driving Safety

Driving laws in Australia and New Zealand treat cannabis similarly to alcohol: driving under the influence is illegal, and THC is detectable on roadside testing. A claimant prescribed THC-containing cannabis products must understand driving restrictions. For claimants in driving-focused roles, cannabis use may preclude return-to-work in those roles.

Cannabis and Workplace Safety

Many employers have drug-free workplace policies. A claimant returning to work on medicinal cannabis may face workplace compliance issues. Legitimate medicinal use differs from recreational use, but employer policies may not always make this distinction. Claimants should be aware of potential workplace implications.

Coverage Assessment Framework

Questions to Ask Before Approving Medicinal Cannabis

• Is the cannabis product TGA-approved or accessed through authorized regulatory pathway (SAS in Australia, licensed in NZ)? Unregulated products lack quality assurance and safety data.
• What is the documented clinical indication? Vague indications (pain, anxiety, sleep) without specific diagnosis warrant closer scrutiny.
• Have conventional treatments been optimized first? Cannabis should not be first-line for anxiety, insomnia, or most pain conditions.
• What is the prescribed THC and CBD ratio? High-THC products carry greater cognitive and safety risks than balanced or CBD-dominant formulations.
• Is the claimant aware of driving and workplace implications? Ensure informed consent and understanding of restrictions.
• How will response be assessed? Define clear endpoints: symptom improvement, functional gain, work capacity improvement.
• What is the trial duration and review plan? Approve cannabis for defined period (e.g., 12 weeks) with structured reassessment, not indefinitely.

Structured Assessment and Monitoring

Red Flags for Discontinuation or Escalation Review

• No objective symptom improvement or functional gain by 12 weeks
• Dose escalation beyond prescriber-recommended range or frequent dose increases
• Claimant reports sedation, cognitive dulling, or impaired function attributable to cannabis
• Cannabis interferes with return-to-work or workplace compliance
• Concurrent opioid or benzodiazepine use (significant polypharmacy risk)
• Evidence of diversion or non-medical use

Deprescribing Medicinal Cannabis

If cannabis is approved for trial and found ineffective, or if circumstances change, deprescribing should be planned. Cannabis withdrawal is not severe compared to benzodiazepines or opioids, but some claimants experience rebound symptoms (pain, anxiety, insomnia). Gradual reduction over 2 to 4 weeks is recommended, with concurrent optimization of alternative symptom management.

Coordination with Workplace and Rehabilitation

Before approving medicinal cannabis, liaise with the claimant's workplace and case manager. Understand workplace drug policies, driving requirements, and safety implications. Inform the claimant explicitly of these considerations. In some cases, medicinal cannabis may be incompatible with return-to-work in safety-sensitive roles, necessitating either role modification or medication change.

Insurer Governance: Medicinal Cannabis Protocol

• Regulatory pathway verification: Before approval, confirm product is TGA-approved or accessed through authorized SAS/licensed pathway. Decline unregulated products.
• Clinical indication assessment: Require specific diagnosis and documented conventional treatment optimization. Vague indications warrant additional scrutiny.
• Trial period approval: Approve medicinal cannabis for defined trial period (typically 8 to 12 weeks) with structured reassessment, not indefinitely.
• Structured monitoring: Require claimant and prescriber documentation of response, side effects, and functional change at regular intervals.
• Cognitive and safety assessment: If claimant is in cognitively demanding role or has driving requirements, explicitly assess impact before approving continued use.
• Workplace coordination: Inform claimant of workplace drug policy implications and driving restrictions. Coordinate with employer if relevant.
• Discontinuation review: If no objective benefit by 12 weeks, or if red flags emerge, mandatory deprescribing discussion with prescriber and claimant.

Common Pitfalls to Avoid

• Assuming medicinal equals safe: Medicinal cannabis has side effects, drug interactions, and safety considerations like any medication.
• Confusing medicinal with recreational use: Clarify distinction; medicinal use through regulatory pathways is legitimate; recreational use is not your responsibility.
• Funding indefinitely without reassessment: Cannabis should be approved for trial period with defined review, not automatically renewed.
• Ignoring cognitive and workplace implications: Cannabis affects cognition and driving; assess these impacts before approving or continuing.
• Accepting vague indications: "Pain," "anxiety," or "wellness" without specific diagnosis warrant stronger scrutiny than specific conditions with evidence.